Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financia...(ax asset ...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Date:4/25/2008
ax asset 143.4 143.7
Other non-current assets 25.3 26.9
_________ _________
Total assets 4,322.1 4,330.1
_________ _________
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses 601.7 674.2
Deferred tax liability 11.3 11.3
Liability to dissenting shareholders 486.8 480.2
Other current liabilities 59.3 96.5
_________ _________
Total current liabilities 1,159.1 1,262.2
Non-current liabilities:
Convertible bonds 1,100.0 1,100.0
Other long term debt 33.4 32.9
Deferred tax liability 344.7 332.4
Other non-current liabilities 371.3 375.6
_________ _________
Total non-current liabilities 1,849.4 1,840.9
_________ _________
Total liabilities 3,008.5 3,103.1
_________ _________
Unaudited US GAAP results for the three months to March 31, 2008
Consolidated Balance Sheets (continued)
March 31, December 31,
2008 2007
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Post Your Comments:
(Date:12/15/2009)... Del. and CHARLOTTESVILLE, Va., Dec. 15 /PRNewswire-FirstCall/ ... and the University of Virginia (UVa) in ... into a strategic research collaboration to enhance ... artery disease (CAD) with a secondary focus ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The collaborative ...
(Date:12/15/2009)... The International Society for Medical Publication ... is continuing to accept abstracts for its 6th ... VA, April 19-21, 2010. This marks the first ... join the organization to submit an abstract to ... 12 AM EST, January 15, 2010. For submission ...
(Date:12/15/2009)... LONDON, Dec. 15 Thomson ... Pharma ® has become the first drug pipeline ... and outcome information. This highly anticipated new content ... this month. ,, Thomson Pharma ... from registries, publications, press releases, conferences, and other ...
(Date:12/14/2009)... 14 Array BioPharma Inc. (Nasdaq: ... today announced that they entered into an agreement ... glucokinase activator program, including ARRY-403, currently being tested ... with Type 2 diabetes. ,, Under ... an upfront payment of $60 million and additional ...
Breaking Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7[0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease[0] The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting[0] Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials[0] Array BioPharma and Amgen Partner in Type 2 Diabetes
... Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX) ... of AppTec Laboratory,Services, Inc., a US-based service ... AppTec offers testing, contract research and,development, and ... fully integrated platform., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
... PALO ALTO, Calif., Jan. 31 CV Therapeutics,Inc. (Nasdaq: ... an Investor Science,Day for the financial community in New ... a.m. EST., The event will be webcast live ... http://www.cvt.com ., About CV Therapeutics, CV Therapeutics, ...
... Discuss Plans for Company in 2008 and Beyond ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ), announced today ... 7, at 10:00 AM EST. President and,Chief Executive ... business strategy. Emisphere is a biopharmaceutical company that,focuses ...
Other Biology Technology:WuXi PharmaTech Completes Acquisition of AppTec 2CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008 2Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3(Date:12/15/2009)... Springer has just signed an agreement with the British ... an affiliation with the journal Biogerontology for ... will appoint one member of the Biogerontology ... issue annually. Springer will sponsor the society and ... Biogerontology on www.springerlink.com . , Biogerontology ...
(Date:12/15/2009)... ancient American horses may have been grazing the ... than previously thought. After plucking ancient DNA from ... researchers used cutting-edge techniques to uncover "genetic fossils" ... to between 7,600 and 10,500 calendar years. This ... of these now-extinct mammals endured longer in the ...
(Date:12/15/2009)... consumers can look forward to ultra-low powered or ... and mobile phones. This is made possible with ... are critical elements for power optimisation and higher ... Analog IC design is the key enabling capability ... the nation in advanced analog and mixed signal ...
Breaking Biology News(10 mins):Late-surviving megafauna exposed by ancient DNA in frozen soil 2Late-surviving megafauna exposed by ancient DNA in frozen soil 3Late-surviving megafauna exposed by ancient DNA in frozen soil 4NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 1Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 2Prince William Health System Completes Merger With Novant Health to Expand Quality Health Care in Northern Virginia 50528 3Infants Should Be Screened for Hip Trouble 50526 1Infants Should Be Screened for Hip Trouble 50526 2Infants Should Be Screened for Hip Trouble 50526 3Christian Childrens Fund Name Change to ChildFund International Official 50524 1Christian Childrens Fund Name Change to ChildFund International Official 50524 2... retroviral resistance gene, called FEZ1, that can mediate a potent ... cell culture. The researchers found that the high level of ... a significant block to retroviral infection ?retroviruses were able to ... were excluded from entering the host cell nucleus. , "We ...
... much more canny predators than previously thought, ecologists have ... British Ecological Society's Journal of Animal Ecology, basking sharks ... at dawn and surfacing at dusk in order to ... As well as shedding new light on basking behaviour, ...
... the abnormal repetition of a genetic sequence can have ... that govern balance and motor coordination. The studies bolster ... by having extra copies of a normal protein, not ... with the rare neurodegenerative disorder spinocerebellar ataxia type 1 ...
Other Biology News:Plankton can run, but can't hide from basking sharks 2Pinpointing the cause of a neurodegenerative disorder 2Pinpointing the cause of a neurodegenerative disorder 3Request Info...
... fastest automated perfusion system. For real-time ... physiology, biophysics, electrochemistry, or general liquid-handling ... 1.5-4 millisecond accuracy Run experiments ... for accuracy and flexibility Turnkey ...
Recombinant Human PTP1B (aa 2-321), CF...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant rat ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |